Welcome to our dedicated page for Redhill Biopharm SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RedHill Biopharma Ltd. files foreign-issuer reports that document its specialty biopharmaceutical business, ADS capital structure and corporate governance. Recent Form 6-K reports incorporate press releases and meeting materials covering Talicia commercialization, RHB-204, RHB-102 and opaganib development disclosures, and clinical or regulatory updates tied to gastrointestinal, infectious-disease and oncology programs.
The company’s SEC record also includes shareholder-meeting notices and voting results for restricted share unit grants and authorized share-capital changes, as well as Nasdaq listing-compliance communications for its American depositary shares. Incorporation-by-reference language links these current reports to Form S-8 equity compensation registrations and Form F-3 shelf registration statements, reflecting recurring disclosure topics around financing capacity, equity plans, governance and material events.
RedHill Biopharma executive Adi Frish filed an initial ownership report showing existing equity interests, not new trades. He reports 27,681 unvested restricted share units tied to American Depositary Shares, 6,280 ADSs that are convertible at any time, stock options over 250,000, 370,000, 600,000 and 750,000 ordinary shares, and 276,810,000 ordinary shares held directly.
RedHill Biopharma Ltd. director Cabilly Shmuel has filed an initial ownership report detailing a substantial equity stake in the company. He directly holds 105,200,000 Ordinary Shares, along with American Depositary Shares, restricted share units and stock options linked to additional Ordinary Shares.
The holdings include 10,520 unvested restricted share units, each tied to one American Depositary Share (ADS) that represents 10,000 Ordinary Shares, and 3,063 ADSs that are convertible at any time at the holder’s election and have no expiration date. He also holds fully vested stock options to purchase 90,000 Ordinary Shares at an exercise price of $4,870 per ADS expiring on March 25, 2030, and options to purchase 180,000 Ordinary Shares at an exercise price of $7,080 per ADS expiring on April 28, 2031.
RedHill Biopharma Ltd. director and Chief Executive Officer Dror Ben-Asher filed an initial ownership report showing substantial equity and option interests in the company. He directly holds 441,350,000 Ordinary Shares and 10,336 American Depositary Shares (ADSs)
The filing also discloses 44,135 unvested restricted share units (RSUs)750,000, 500,000, 900,000, and 1,100,000 Ordinary Shares at exercise prices of $5,000, $5,000, $4,870, and $7,080 per ADS, expiring between 2028 and 2031.
RedHill Biopharma Ltd. reported that at its Extraordinary General Meeting of Shareholders held on March 5, 2026, all resolutions proposed to shareholders were duly approved. The company also states that this report is incorporated by reference into multiple existing Form S-8 and Form F-3 registration statements previously filed with the U.S. securities regulator.
RedHill Biopharma reports that full U.S. sales and operational launch of Talicia has begun under a joint commercialization agreement with Cumberland Pharmaceuticals. The launch is managed by Talicia Holdings Inc. (THI), a jointly controlled operating entity owned 70% by RedHill and 30% by Cumberland.
This operational start follows a previously announced joint commercialization model that included Cumberland’s $4 million strategic investment. The partners aim to accelerate Talicia’s market penetration and reach by integrating commercial resources and coordinating promotion activities.
Talicia is the only FDA‑approved all‑in‑one, low‑dose rifabutin‑based therapy for H. pylori infection and is listed as an empiric first‑line treatment option in the 2024 American College of Gastroenterology guideline. H. pylori affects about 35% of U.S. adults, with an estimated 1.6 million patients treated annually, making this a large target market. RedHill is also pursuing Talicia approvals and licensing opportunities in additional territories, including the UK, the Middle East, and other ex‑U.S. markets.
RedHill Biopharma is registering up to 6,465,559 ADSs for resale by YA II PN, LTD. under a standby equity purchase arrangement. The ADSs cover up to 5,000,000 Advance Shares, 386,593 Initial Equity Shares, 590,446 ADSs from pre-funded warrants and 488,520 Commitment Shares.
Under the Purchase Agreement, YA has committed, subject to conditions and ownership caps, to buy up to $25.0 million of ADSs over 36 months, plus $1.0 million already raised via Initial Equity Shares and pre-funded warrants. As of January 21, 2026, 5,112,885 ADSs were outstanding; if all 6,465,559 registered ADSs were issued, they would represent about 55.84% of outstanding ADSs.
RedHill Biopharma Ltd. has called an Extraordinary General Meeting for March 5, 2026 in Tel Aviv to vote on four key proposals. Shareholders will be asked to approve RSU grants to four independent non-executive directors, including 9,000 ADSs each for Drs. Reed, Cabilly and Mamluk and 12,500 ADSs for Ofer Tsimchi, vesting quarterly over two years. A separate proposal seeks approval for 38,000 ADS RSUs for CEO and Chairman Dror Ben-Asher and 27,000 ADS RSUs for Chief Commercial Officer and director Rick D. Scruggs, also vesting over two years. Another proposal would increase authorized share capital from NIS 1.6 billion to NIS 5.0 billion, raising the ordinary share authorization from 159,994,000,000 to 499,994,000,000 shares. Holders of record of ADSs as of January 23, 2026, when 51,128,851,000 ordinary shares (5,112,885 ADSs) were outstanding, may vote, with a special majority requirement applying to the CEO grant.
RedHill Biopharma Ltd. has filed a resale registration for up to 6,465,559 American Depositary Shares (ADSs) that may be offered from time to time by YA II PN, Ltd. under a standby equity purchase arrangement. The total covers 5,000,000 ADSs that RedHill may sell to YA, plus ADSs already issued or issuable as Initial Equity Shares, Pre-Funded Warrants and Commitment Shares.
RedHill will not receive proceeds from YA’s resale of these ADSs, but may raise up to $25.0 million in gross proceeds from selling Advance Shares to YA over 36 months, in addition to $1.0 million already raised via Initial Equity Shares and Pre-Funded Warrants. As of January 21, 2026, 5,112,885 ADSs were outstanding, and if all 6,465,559 registered ADSs were issued, they would equal about 55.84% of shares then outstanding.
The filing highlights dilution and price pressure risks from this structure, alongside other financing tools such as an existing $10 million equity line and an ATM program. It also notes preliminary 2025 net revenues of $6.5–$7.5 million versus $8.0 million in 2024 and estimated year-end 2025 liquidity of about $4.1 million, underscoring RedHill’s need for external capital.
RedHill Biopharma Ltd. has called an extraordinary general meeting of shareholders for March 5, 2026, to be held at its Tel-Aviv offices. The notice states that only holders of record of ADSs at the close of business on January 23, 2026 are entitled to receive notice and vote.
The board of directors recommends that shareholders vote “FOR” the proposals described in the proxy materials. ADS holders are asked to return their proxies by the deadline on their proxy form, and shareholders may submit written position statements to the company by February 23, 2026.
If a quorum is not reached within half an hour of the scheduled time, the meeting will be adjourned to a later date as determined by the board. The notice and related documents will be available on RedHill’s website and on the SEC website.